Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.15Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -17.53%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive achievements, particularly in international revenue growth, radiopharmaceutical platform progress, and strong financial positioning. However, these were balanced by challenges, including revenue decline in the U.S., increased net loss, and difficulties in patient enrollment for trials. The strategic realignment is expected to address some of these challenges.Company Guidance
During the Y-mAbs Therapeutics earnings call for Q4 and full year 2024, the company provided guidance for the first quarter and full year of 2025. They anticipate total net revenue for 2025 to be between $75 million and $90 million and expect Q1 2025 revenue to range from $18 million to $21 million. Operating expenses excluding cost of goods sold are projected to be between $116 million and $121 million for 2025. The company ended 2024 with $67.7 million in cash and cash equivalents and expects their resources to support operations into 2027. Y-mAbs reported 2024 total revenue of $87.7 million, with DANYELZA net product revenues of $85.2 million and a steady U.S. market share of 15%-17%. They also highlighted strong international sales growth, particularly in Western Asia, Eastern Asia, and Latin America. The company is advancing its SADA PRIT radiopharmaceutical platform, with plans to share additional data in Q2 2025.DANYELZA Revenue Growth
Total DANYELZA net product revenues for the full year 2024 were $85.2 million, with a 5% increase in Q4 2024 revenue compared to Q4 2023, driven by strong international markets.
Radiopharmaceutical Platform Progress
Achieved proof of concept with the SADA PRIT platform in the GD2-SADA Phase I trial, with no dose-limiting toxicities and positive tumor targeting and binding.
Strong International Performance
Ex-U.S. DANYELZA revenues increased by 78% in Q4 2024 compared to Q4 2023, driven by launches in Western Asia and increased sales in Eastern Asia and Latin America.
Financial Position
Ended 2024 with $67.7 million in cash and cash equivalents, with an annual cash investment of $11.4 million, below stated guidance, supporting plans into 2027.
Business Realignment Strategy
Implemented a strategic realignment to focus on two distinct business units, DANYELZA and Radiopharmaceuticals, to accelerate development and capital efficiency.
---
YMAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
YMAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $5.19 | $4.96 | -4.43% |
| Nov 08, 2024 | $15.55 | $15.48 | -0.45% |
| Aug 12, 2024 | $11.21 | $9.95 | -11.24% |
| May 07, 2024 | $17.21 | $13.61 | -20.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Y-Mabs Therapeutics (YMAB) report earnings?
Y-Mabs Therapeutics (YMAB) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Y-Mabs Therapeutics (YMAB) earnings time?
Y-Mabs Therapeutics (YMAB) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is YMAB EPS forecast?
YMAB EPS forecast for the fiscal quarter 2025 (Q1) is -0.21.
---